[1]常晓娟,赵千渃,赵 璇,等.阿立哌唑联合舍曲林治疗精神分裂症伴抑郁症临床疗效观察*[J].陕西医学杂志,2020,49(12):1669-1672.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.035]
　CHANG Xiaojuan,ZHAO Qianruo,ZHAO Xuan,et al.Clinical efficacy of aripiprazole combined with sertraline in treatment of schizophrenia with depression[J].,2020,49(12):1669-1672.[doi:DOI:10.3969/j.issn.1000-7377.2020.12.035]
点击复制

阿立哌唑联合舍曲林治疗精神分裂症伴抑郁症临床疗效观察*
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
49
期数:
2020年12期
页码:
1669-1672
栏目:
药物与临床
出版日期:
2020-12-05

文章信息/Info

Title:
Clinical efficacy of aripiprazole combined with sertraline in treatment of schizophrenia with depression
作者:
常晓娟1; 赵千渃1; 赵 璇2; 杨小龙2; 常耀华3
1.陕西省汉中市中心医院(汉中 723000); 2.兰州市第三人民医院精神科(兰州 730050); 3.山西省汾阳医院精神科(汾阳 032200)
Author(s):
CHANG Xiaojuan; ZHAO Qianruo; ZHAO Xuan; et al.
Hanzhong Central Hospital,Shaanxi Province(Hanzhong 723000)
关键词:
精神分裂症;  抑郁症;  阿立哌唑;  舍曲林;  阳性和阴性症状量表;  卡尔加里精神分裂症抑郁量表
Keywords:
Schizophrenia;  Depression;  Aripiprazole;  Sertraline;  PANSS;  CDSS-C
分类号:
R749.05
DOI:
DOI:10.3969/j.issn.1000-7377.2020.12.035
文献标志码:
A
摘要:
目的:观察阿立哌唑联合舍曲林治疗精神分裂症伴抑郁症的临床疗效。方法:96例精神分裂症伴抑郁症患者随机分为观察组和对照组,每组48例。对照组给予阿立哌唑治疗,观察组则给予阿立哌唑联合舍曲林治疗。比较两组患者治疗前、治疗16周后精神症状评分[阳性和阴性症状量表(PANSS)评分]、认知功能评分[威斯康星卡片分类实验(WCST)完成分类数与持续性错误数评分以及成人韦氏智能量表(WAIS)数字广度评分]、抑郁症状评分[卡尔加里精神分裂症抑郁量表(CDSS-C)评分]以及血清蛋白因子[白细胞介素-6(IL-6)、钙结合蛋白S100β、神经营养因子-3(NT-3)]水平。结果:治疗16周后,两组患者PANSS阳性症状、阴性症状、一般精神病理评分均较治疗前降低,且观察组低于对照组(均P<0.05); 两组患者WCST完成分类数评分、WAIS数字广度评分均较治疗前提高,且观察组高于对照组; WCST持续性错误数评分较治疗前降低,且观察组低于对照组(均P<0.05); 两组患者CDSS-C评分均较治疗前降低,且观察组低于对照组(均P<0.05); 两组患者IL-6、S100β水平均较治疗前降低,且观察组低于对照组(均P<0.05); 两组患者NT-3水平高于治疗前,且观察组高于对照组(均P<0.05)。结论:阿立哌唑联合舍曲林治疗精神分裂症伴抑郁症疗效优于单用阿立哌唑,可更有效改善认知功能与抑郁症状,其机制可能与调节IL-6、S100β、NT-3等血清蛋白因子水平的作用有关。
Abstract:
Objective:To analyze the effects of aripiprazole alone or combined with sertraline on the score of Positive and Negative Symptom Scale(PANSS),Score of Calgary Depression Scale for Schizophrenia(CDSS-C)and serum protein factors in the treatment of schizophrenia with depression.Methods:A total of 96 patients with schizophrenia and depression were enrolled in the study.The patients were divided into observation group and control group by random number table method,with 48 cases in each group.Psychiatric Symptoms(PANSS)scores were compared between the two groups after 16 weeks of treatment,and cognitive function [completed categories and persistent errors of Wisconsin Card Sorting Test(WCST),digit span of Wechsler Adult Intelligence Scale(WAIS)],Depressive Symptoms(CDSS-C)score and serum protein factors [interleukin-6(IL-6),calcium binding protein S100β(S100β),neurotrophin-3(NT-3)] were recorded before treatment and after 16 weeks of treatment.Results:After 16 weeks of treatment,the scores of positive symptoms,negative symptoms and general psychopathology of PANSS in observation group were lower than those in control group(all P<0.05).The number of WCST completed categories and digit span of WAIS in the two groups were improved compared with those before treatment,and the two indexes in observation group were higher than those in control group,and the number of WCST persistent errors was decreased compared with that before treatment,and the index in observation group was lower than that in control group(all P<0.05).The CDSS-C scores in the two groups were decreased compared with those before treatment,and the score in observation group was lower than that in control group(all P<0.05).The levels of IL-6 and S100β in the two groups were decreased compared with those before treatment,and the levels in observation group were lower than those in control group,and the NT-3 level was increased compared with that before treatment,and the level in observation group was higher than that in control group(all P<0.05).Conclusion:Aripiprazole combined with sertraline has better efficacy than aripiprazole alone in the treatment of schizophrenia with depression,and it can improve cognitive function and depressive symptoms more effectively.And its mechanism may be related to the regulation of serum protein factors IL-6,S100β and NT-3.

参考文献/References:

[1] 刘 洋,蔡 军.精神分裂症认知功能训练新进展[J].中国康复,2016,31(5):335-338.
[2] 潘令仪,沈含冰,张佳宝,等.针灸对缓解期精神分裂症患者脑功能效应影响的研究[J].陕西中医,2020,41(6):819-822.
[3] 曹 峰,谢渭根.奥氮平与齐拉西酮治疗精神分裂症的疗效及对糖脂代谢的影响[J].中华全科医学,2020,18(2):217-219,232.
[4] 刘显阳,张小刚,刘 飞,等.内观疗法对精神分裂症患者应对方式的影响[J].陕西医学杂志,2017,46(1):63-65.
[5] 陈 岩,郭雪梅,刘 伟,等.舍曲林对稳定期精神分裂症患者认知功能的影响[J].山西医药杂志,2015,12(16):1932-1933.
[6] 平军辉,仲照希,潘 飞,等.帕利哌酮缓释片联合舍曲林治疗残留型精神分裂症35例[J].医药导报,2016,35(10):1076-1078.
[7] 白晓英,刘建武,杨 睿,等.精神分裂症患者劳动能力鉴定PANSS量表应用分析[J].陕西医学杂志,2009,38(4):508-509.
[8] 邹义壮,崔界峰,王 健,等.精神分裂症认知功能成套测验中文版临床信度及效度的研究[J].中华精神科杂志,2009,42(1):29-33.
[9] 张振明.卡尔加里精神分裂症抑郁量表(中文版)信效度初步分析[J].中国现代药物应用,2014,8(24):210-211.
[10] 杨建中.探讨个性化干预对精神分裂症患者社会功能康复的促进作用[J].世界最新医学信息文摘,2018,18(91):289.
[11] 寇泽刚.阿立哌唑、喹硫平和利培酮对精神分裂症患者甲状腺素水平的影响[J].蚌埠医学院学报,2015,40(9):1184-1185.
[12] 谭 樨.阿立哌唑与利培酮治疗首发精神分裂症患者的临床疗效及对认知功能的影响[J].检验医学与临床,2015,14(17):2603-2604.
[13] 李 涛,李界兴,尚同军,等.奥氮平片与利培酮片治疗男性精神分裂症疗效、安全性及对患者生活质量影响对比研究[J].陕西医学杂志,2019,48(5):657-660.
[14] 段元东,张京学,韩成有,等.阿立哌唑联合艾司西酞普兰对首发精神分裂症患者认知功能及社会功能的疗效[J].国际精神病学杂志,2018,45(4):608-621.
[15] 白延欣,方 袁,牟世伟.阿立哌唑、利培酮和奥氮平对精神分裂症病人糖脂代谢及体重影响的临床观察分析[J].内蒙古医科大学学报,2018,40(5):526-528.
[16] 刘晓凤,郑华东.奥氮平和齐拉西酮对精神分裂症患者代谢综合征的影响研究[J].陕西医学杂志,2017,46(12):1773-1774.
[17] 胡 江.帕罗西汀对难治性精神分裂症阴性症状临床研究[J].陕西医学杂志,2019,48(1):108-111.
[18] 亓国锋,肖艳灿,梁瑞红,等.养血清脑颗粒治疗精神分裂症急性发作伴抑郁症疗效及对患者神经递质影响的研究[J].陕西中医,2018,39(12):1768-1770.
[19] 王永红,王海涛,赵 飞.舍曲林联合抗精神病药治疗精神分裂症后抑郁的效果观察[J].临床合理用药杂志,2018,11(13):87-88.

相似文献/References:

[1]刘飞虎,吴强驹,崔小花,等.精神分裂症患者与饮用水锂元素水平关系及相关基因调查研究*[J].陕西医学杂志,2019,(4):535.
　LIU Feihu,WU Qiangju,CUI Xiaohua,et al.Relationship between schizophrenia patients and lithium levels in drinking water and related genes[J].,2019,(12):535.
[2]李 涛,李界兴△,尚同军,等.奥氮平片与利培酮片治疗男性精神分裂症疗效、安全性及对患者生活质量影响对比研究[J].陕西医学杂志,2019,(5):657.
　LI Tao,LI Jiexing,SHANG Tongjun,et al.A comparative study on the efficacy, safety and impact of olanzapine tablets and risperidone tablets on male patients with schizophrenia[J].,2019,(12):657.
[3]阎得胜,闫可域,祁 婧,等.老年患者341例抗精神病用药分析*[J].陕西医学杂志,2020,49(3):337.
　YAN Desheng,YAN Keyu,QI Jing,et al.Prescription analysis of 341 elderly patients with antipsychotics[J].,2020,49(12):337.
[4]张 帆,刘睿华,孙 维,等.草酸艾司西肽普兰联合曲唑酮治疗抑郁症126例疗效观察*[J].陕西医学杂志,2020,49(10):1332.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.035]
　ZHANG Fan,LIU Ruihua,SUN Wei,et al.Efficacy of escitalopram oxalate combined with trazodone in treatment of 126 patients with depression[J].,2020,49(12):1332.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.035]
[5]姜金波,吴 迪,刘文明,等.精神分裂症幻听的磁共振成像研究进展[J].陕西医学杂志,2021,50(4):507.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.033]
　JIANG Jinbo,WU Di,LIU Wenming,et al.Research progress of magnetic resonance imagingon auditory hallucinations in schizophrenia[J].,2021,50(12):507.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.033]
[6]万育辰,王化宁,吕辉珍,等.氨磺必利对精神分裂症伴抑郁患者正负性情绪、应对方式的影响[J].陕西医学杂志,2021,50(9):1131.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.022]
　WAN Yuchen,WANG Huaning,LYU Huizhen,et al.Effect of amsulapride on positive and negative emotions and coping styles in schizophrenic patients with depression[J].,2021,50(12):1131.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.022]
[7]张 倩,付建军.干扰素和直接作用抗病毒药物治疗慢性丙型肝炎所致抑郁症发病机制研究进展[J].陕西医学杂志,2022,51(6):760.[doi:DOI:10.3969/j.issn.1000-7377.2022.06.028]
　ZHANG Qian,FU Jianjun.Research progress on pathogenesis of depression caused by interferon and direct acting antiviral drugs in treatment of chronic hepatitis C[J].,2022,51(12):760.[doi:DOI:10.3969/j.issn.1000-7377.2022.06.028]

备注/Memo

备注/Memo:
*陕西省卫生和计划生育委员会科研课题(2015JM13064)
更新日期/Last Update: 2020-12-11